357 related articles for article (PubMed ID: 20220779)
21. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome.
Cordoba I; González-Porras JR; Nomdedeu B; Luño E; de Paz R; Such E; Tormo M; Vallespi T; Collado R; Xicoy B; Andreu R; Muñoz JA; Solé F; Cervera J; del Cañizo C;
Cancer; 2012 Jan; 118(1):127-33. PubMed ID: 21717439
[TBL] [Abstract][Full Text] [Related]
22. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
23. Systematic screening at diagnosis of -5/del(5)(q31), -7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics.
Beyer V; Castagné C; Mühlematter D; Parlier V; Gmür J; Hess U; Kovacsovics T; Meyer-Monard S; Tichelli A; Tobler A; Jacky E; Schanz U; Bargetzi M; Hagemeijer A; de Witte T; van Melle G; Jotterand M
Cancer Genet Cytogenet; 2004 Jul; 152(1):29-41. PubMed ID: 15193439
[TBL] [Abstract][Full Text] [Related]
24. Gene stage-specific expression in the microenvironment of pediatric myelodysplastic syndromes.
Roela RA; Carraro DM; Brentani HP; Kaiano JH; Simão DF; Guarnieiro R; Lopes LF; Borojevic R; Brentani MM
Leuk Res; 2007 May; 31(5):579-89. PubMed ID: 17092558
[TBL] [Abstract][Full Text] [Related]
25. Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
Haferlach C; Bacher U; Tiu R; Maciejewski JP; List A
Cancer Genet Cytogenet; 2008 Dec; 187(2):101-11. PubMed ID: 19027491
[TBL] [Abstract][Full Text] [Related]
26. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
Oliva EN; Cuzzola M; Nobile F; Ronco F; D'Errigo MG; Laganà C; Morabito F; Galimberti S; Cortelezzi A; Aloe Spiriti MA; Specchia G; Poloni A; Breccia M; Ghio R; Finelli C; Iacopino P; Alimena G; Latagliata R
Eur J Haematol; 2010 Sep; 85(3):231-5. PubMed ID: 20491881
[TBL] [Abstract][Full Text] [Related]
27. Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression.
Sridhar K; Ross DT; Tibshirani R; Butte AJ; Greenberg PL
Blood; 2009 Nov; 114(23):4847-58. PubMed ID: 19801443
[TBL] [Abstract][Full Text] [Related]
28. DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation.
Hopfer O; Komor M; Koehler IS; Schulze M; Hoelzer D; Thiel E; Hofmann WK
Exp Hematol; 2007 May; 35(5):712-23. PubMed ID: 17577921
[TBL] [Abstract][Full Text] [Related]
29. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities.
Chen G; Zeng W; Miyazato A; Billings E; Maciejewski JP; Kajigaya S; Sloand EM; Young NS
Blood; 2004 Dec; 104(13):4210-8. PubMed ID: 15315976
[TBL] [Abstract][Full Text] [Related]
30. Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks.
Sundaravel S; Kuo WL; Jeong JJ; Choudhary GS; Gordon-Mitchell S; Liu H; Bhagat TD; McGraw KL; Gurbuxani S; List AF; Verma A; Wickrema A
Clin Cancer Res; 2019 Sep; 25(18):5638-5649. PubMed ID: 31308061
[TBL] [Abstract][Full Text] [Related]
31. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.
Eisenmann KM; Dykema KJ; Matheson SF; Kent NF; DeWard AD; West RA; Tibes R; Furge KA; Alberts AS
Oncogene; 2009 Oct; 28(39):3429-41. PubMed ID: 19597464
[TBL] [Abstract][Full Text] [Related]
32. Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.
Douet-Guilbert N; Herry A; LE Bris MJ; Guéganic N; Bovo C; Morel F; DE Braekeleer M
Anticancer Res; 2011 Mar; 31(3):1007-10. PubMed ID: 21498729
[TBL] [Abstract][Full Text] [Related]
33. Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine.
Giachelia M; D'Alò F; Fabiani E; Saulnier N; Di Ruscio A; Guidi F; Hohaus S; Voso MT; Leone G
Leuk Res; 2011 Apr; 35(4):465-71. PubMed ID: 20869114
[TBL] [Abstract][Full Text] [Related]
34. Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.
Pellagatti A; Marafioti T; Paterson JC; Malcovati L; Della Porta MG; Jädersten M; Pushkaran B; George TI; Arber DA; Killick S; Giagounidis A; Hellström-Lindberg E; Cazzola M; Wainscoat JS; Boultwood J
Br J Haematol; 2009 Jun; 146(1):86-90. PubMed ID: 19438482
[TBL] [Abstract][Full Text] [Related]
35. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
Fidler C; Watkins F; Bowen DT; Littlewood TJ; Wainscoat JS; Boultwood J
Haematologica; 2004 Jul; 89(7):865-6. PubMed ID: 15257941
[TBL] [Abstract][Full Text] [Related]
36. Deregulation of microRNAs in myelodysplastic syndrome.
Rhyasen GW; Starczynowski DT
Leukemia; 2012 Jan; 26(1):13-22. PubMed ID: 21852786
[TBL] [Abstract][Full Text] [Related]
37. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
38. Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.
Oliva EN; Cuzzola M; Aloe Spiriti MA; Poloni A; Laganà C; Rigolino C; Morabito F; Galimberti S; Ghio R; Cortelezzi A; Palumbo GA; Sanpaolo G; Finelli C; Ricco A; Volpe A; Rodà F; Breccia M; Alimena G; Nobile F; Latagliata R
Ann Hematol; 2013 Jan; 92(1):25-32. PubMed ID: 22983750
[TBL] [Abstract][Full Text] [Related]
39. [Transcriptome profiling of marrow mononuclear cells of patients with myelodysplastic syndrome using cDNA microarray analysis].
Qian J; Chen ZX; Wang W; Cen JN; Xue YQ
Zhonghua Yi Xue Za Zhi; 2004 Aug; 84(15):1260-4. PubMed ID: 15387962
[TBL] [Abstract][Full Text] [Related]
40. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH.
Evers C; Beier M; Poelitz A; Hildebrandt B; Servan K; Drechsler M; Germing U; Royer HD; Royer-Pokora B
Genes Chromosomes Cancer; 2007 Dec; 46(12):1119-28. PubMed ID: 17823930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
